Table 3. Profile of antibiotic use in patients hospitalized for COVID-19 with bacterial superinfection.
| Variable | Levels | n | % |
|---|---|---|---|
| Days of antibiotic treatment | 1–7 days | 128 | 62.7 |
| 8–14 days | 51 | 25.0 | |
| 15 or more days | 25 | 12.3 | |
| Number of antibiotics | One | 123 | 60.3 |
| Two | 35 | 17.2 | |
| Three or more | 46 | 22.5 | |
| Type of antibiotic treatment | Only one | 123 | 60.3 |
| Multiple (2 or more) | 81 | 39.7 | |
| Antibiotic used | Ampicillin/sulbactam | 115 | 56.4 |
| Piperacillin/tazobactam | 61 | 29.9 | |
| Meropenem | 38 | 18.6 | |
| Ciprofloxacin | 34 | 16.7 | |
| Ceftriaxone | 31 | 15.2 | |
| Cefepime | 17 | 8.3 | |
| Ceftaroline | 14 | 6.9 | |
| Cefazolin | 12 | 5.9 | |
| Linezolid | 12 | 5.9 | |
| Vancomycin | 9 | 4.4 | |
| Clindamycin | 9 | 4.4 | |
| Aztreonam | 6 | 2.9 | |
| Gentamicin | 3 | 1.5 | |
| Daptomycin | 2 | 1.0 | |
| Amikacin | 2 | 1.0 | |
| Anti-tuberculosis (HRZE) | 2 | 1.0 | |
| Moxifloxacin | 1 | 0.5 | |
| Trimethoprim-sulfamethoxazole | 1 | 0.5 | |
| Ceftazidime/avibactam | 1 | 0.5 |